Ivabradine, coronary artery disease, and heart failure: Beyond rhythm control

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 689-700

  Scicchitano, Pietro ^a   Cortese, Francesca ^a   Ricci, Gabriella ^a   Carbonara, Santa ^a   Moncelli, Michele ^a   Iacoviello, Massimo ^a   Cecere, Annagrazia ^a   Gesualdo, Michele ^a   Zito, Annapaola ^a   Caldarola, Pasquale ^b   Scrutinio, Domenico ^c   Lagioia, Rocco ^c   Riccioni, Graziano ^d   Ciccone, Marco Matteo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b San Paolo Hospital   (Italy)

^c IRCCS   (Italy)

^d SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

Cardiac ischemic disease; Chronic heart failure; Funny current; Heart rate reduction; Heart rate lowering drugs

Indexed keywords

HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; IVABRADINE; BENZAZEPINE DERIVATIVE;

ACTION POTENTIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; HEART FAILURE; HEART RATE; POTASSIUM CURRENT; REVIEW; SODIUM CURRENT; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN;

ANIMALS; BENZAZEPINES; CORONARY ARTERY DISEASE; HEART FAILURE; HEART RATE; HUMANS;

EID: 84901941244     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S60591     Document Type: Review

References (92)

1. Giannoglou GD, Chatzizisis YS, Zamlis C, Parcharidis GE, Mikhailidis DP, Louridas GE. Elevated heart rate and atherosclerosis. An overview of the pathogenetic mechanisms. Int J Cardiol. 2008; 126(3):302-312.
2. Scicchitano P, Carbonara S, Ricci G, et al. HCN channels and heart rate. Molecules. 2012;17(4):4225-4235.
3. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284(2):H676-H682.
4. Parakh N, Bhargara B. Rate control with Ivabradine. Am J Cardiovasc Drugs. 2011;11(1):1-12.
5. Thollon C, Villaine JP. If inhibition in cardiovascular diseases. Adv Pharmacol. 2010;59:53-92.
6. Tardif JC. Clinical results of If current inhibitor by ivabradine. Drugs. 2007;67 Suppl 2:S35-S41.
7. Riccioni G, Vitulano N, D'Orazio N. Ivabradine: beyond heart rate control. Adv Ther. 2009;26(1):12-24.
8. Menown IB. Ivabradine: a new strategy for management of stable angina. Br J Hosp Med. 2007;68(6):21-25.
9. Thollon C, Bidouard JP, Cambarrat C, et al. Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+) -S 16257.Eur J Pharmacol. 1997;339(1):43-51.
10. Ragueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther. 1998;64(2):192-203.
11. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112(1):37-42.
12. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrialnode cells. Br J Pharmacol. 1996;118(4):1051-1057.
13. Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node If channels by ivabradine. J Gen Physiol. 2002;120(1):1-13.
14. Savelieva I, Camm AJ. If inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31(2):95-107.
15. Rosa GM, Ferrero S, Ghione P, Valbusa A, Brunelli C. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. Expert Opin Drug Metab Toxicol. 2014;10(2): 279-291.
16. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64(16):1757-1765.
17. Borer JS, Fox K, Jaillon P, Lerebours G; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an If inhibitor,in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817-823.
18. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529-2536.
19. Camm AJ. How does pure heart rate lowering impact on cardiac tolerability? Eur Heart J Suppl. 2006;8 (Suppl D):D9-D15.
20. Murat SN, Orcan S, Akdemir R, Dogan M, Kara E, Balci M. Arrhythmic effects of ivabradine in patients with coronary artery disease. Clin Invest Med. 2009;32(5):E322-E326.
21. Scott AE, Kruszewski K, Leslie SJ. Sinus node If channel inhibition - a new therapeutic approach to heart rate lowering. Curr Drug Therapy. 2009;4(1):12-18.
22. Swedberg K, Komajda M, Bohm M, et al; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-885.
23. Custodis F, Baumhäkel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117(18):2377-2387.
24. Dominguez-Rodriguez A, Blanco-Palacios G, Abreu-Gonzales P. Increased heart rate and atherosclerosis: potential implications of ivabradine therapy. World J Cardiol. 2011;3(4):101-104.
25. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807-816.
26. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817-821.
27. Bruguera Cortada J, Varela A. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice. Am J Cardiovasc Drugs. 2009;9 Suppl:9-12.
28. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337-2345.
29. Tendera M, Talajic M, Robertson M, et al; BEAUTIFUL Investigators. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol. 2011;107(6):805-811.
30. Ferrari R. A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease). Eur Heart J. 2009;11(Suppl D): 19-27.
31. Lucats L, Ghaleh B, Colin P, Monnet X, Bizé A, Berdeaux A. Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening. Br J Pharmacol. 2007;150(3): 335-341.
32. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol. 2013;168(2):789-794.
33. Köster R, Kaehler J, Meinertz T; REDUCTION Study Group. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study. Am Heart J. 2009;158(4):51-57.
34. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008;29(18):2265-2275.
35. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226(4671):180-182.
36. Prosi M, Perktold K, Ding Z, Friedman MH. Influence of curvature dynamics on pulsatile coronary artery flow in a realistic bifurcation model. J Biomech. 2004;37(11):1767-1775.
37. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008;154(4):749-757.
38. Rogowski O, Shapira I, Shirom A, Melamed S, Toker S, Berliner S. Heart rate and microinflammation in men: a relevant atherothrombotic link. Heart. 2007;93(8):940-944.
39. Monnet X, Ghaleh B, Colin P, de Curzon OP, Giudicelli JF, Berdeaux A. Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning. J Pharmacol Exp Ther. 2001;299(3): 1133-1139.
40. Monnet X, Colin P, Ghaleh B, Hittinger L, Giudicelli JF, Berdeaux A. Heart rate reduction during exercise-induced myocardial ischaemia and stunning. Eur Heart J. 2004;25(7):579-586.
41. Lucats L, Ghaleh B, Monnet X, Colin P, Bizé A, Berdeaux A. Conversion of post-systolic wall thickening into ejectional thickening by selective heart rate reduction during myocardial stunning. Eur Heart J. 2007;28(7):872-879.
42. Pagidipati NJ, Gaziano TA. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation. 2013;127(6):749-756.
43. Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153(8):1589-1601.
44. Custodis F, Schirmer SH, Baumhäkel M, Heusch G, Böhm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol. 2010;56(24):1973-1983.
45. Skalidis EI, Hamilos MI, Chlouverakis G, Zacharis EA, Vardas PE. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease. Atherosclerosis. 2011;215(1):160-165.
46. Zuanetti G, Mantini L, Hernández-Bernal F, et al. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insights from the GISSI-2 study. Eur Heart J. 1998;19 Suppl F:F19-F26.
47. Riccioni G. Ivabradine: an intelligent drug for the treatment of ischemic heart disease. Molecules. 2012;17(11):13592-13604.
48. Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem. 2013;20(4):1817-1823.
49. Mulder P, Barbier S, Chagraoui A, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109(13):1674-1679.
50. Fasullo S, Cannizzaro S, Maringhini G, et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009;15(10):856-863.
51. Riccioni G. Ivabradine: from molecular basis to clinical effectiveness. Adv Ther. 2010;27(3):160-167.
52. Rozanski A, Qureshi E, Bauman M, Reed G, Pillar G, Diamond GA. Peripheral Arterial Responses to treadmill exercise among healthy subjects and atherosclerotic patients. Circulation. 2001;103:2084-2089.
53. Böhm M, Reil JC. Perspectives of I(f) inhibition by ivabradine in cardiology. Drugs. 2007;67 Suppl 2:43-49.
54. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275(2): 659-666.
55. Linka AZ, Sklenar J, Wei K, Jayaweera AR, Skyba DM, Kaul S. Assessment of transmural distribution of myocardial perfusion with contrast echocardiography. Circulation. 1998;98(18):1912-1920.
56. Van Camp G, Ay T, Pasquet A, et al. Quantification of myocardial blood flow and assessment of its transmural distribution with real-time power modulation myocardial contrast echocardiography. J Am Soc Echocardiogr. 2003;16(3):263-270.
57. Schulz R, Heusch G. The relationship between regional blood flow and contractile function in normal, ischemic, and reperfused myocardium. Basic Res Cardiol. 1998;93(6):455-462.
58. Decking UK, Schrader J. Spatial heterogeneity of myocardial perfusion and metabolism. Basic Res Cardiol. 1998;93(6):439-445.
59. Hsu LY, Groves DW, Aletras AH, Kellman P, Arai AE. A fully quantitative pixel-wise measurement of myocardial blood flow by contrast-enhanced first-pass CMR perfusion imaging: microsphere validation in dogs and feasibility study in humans. JACC Cardiovasc Imaging. 2012;5(2):154-166.
60. Fox K, Garcia MA, Ardissino D, et al; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341-1381.
61. Canet E, Lerebours G, Vilaine JP. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine. Ann N Y Acad Sci. 2011;1222:90-99.
62. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166(4):654-661. e6.
63. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540-548.
64. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther. 2011;25(6):531-537.
65. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67(3):393-405.
66. Marquis-Gravel G, Tardif JC. Ivabradine: the evidence of its therapeutic impact in angina. Core Evid. 2008;3(1):1-12.
67. Vaillant F, Timour Q, Descotes J, et al. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study. J Cardiovasc Pharmacol. 2008;52(6):548-554.
68. Vaillant F, Dehina L, Mazzadi A, et al. Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: role of myocyte structure and myocardial perfusion. Resuscitation. 2011;82(8):1092-1019.
69. Vaillant F, Dehina L, Dizerens N, et al. Ivabradine but not propranolol delays the time to onset of ischaemia-induced ventricular fibrillation by preserving myocardial metabolic energy status. Resuscitation. 2013;84(3):384-390.
70. Heusch G. A BEAUTIFUL lesson - ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur Heart J. 2009;30(19):2300-2301.
71. Dickstein K, Cohen-Solal A, Filippatos G, et al; ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10(10):933-989.
72. Heusch G. Heart rate and heart failure. Not a simple relationship.Circ J. 2011;75(2):229-236.
73. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blockers dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150:784-794.
74. Doughty RN, Whalley GA, Walsh HA, Gamble GD, López-Sendón J, Sharpe N; CAPRICORN Echo Substudy Investigators. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004;109(2):201-206.
75. Ferrari R; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med. 2006;166(6):59-66.
76. Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). 2004;18(1):57-66.
77. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101(6):865-869.
78. Ekman I, Chassany O, Komajda M. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32(19):2395-2404.
79. Teerlink JR. Ivabradine in heart failure - no paradigm SHIFT ... yet. Lancet. 2010;376(9744):847-849.
80. Fang Y, Debunne M, Vercauteren M, et al. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol. 2012;59(3): 260-267.
81. Reil JC, Reil GH, Böhm M. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. Trends Cardiovasc Med. 2009;19(5):152-157.
82. Setakis E, Kassianos G, Cockle S. Adverse events and subsequent changes in beta-blocker treatment in coronary heart disease patients in UK primary care. Eur Heart J. 2009;30:974. Suppl 1. Abstract P5476.
83. Couvreur N, Tissier R, Pons S, et al. Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long-term increase in FKBP12/12.6 expression. Eur Heart J. 2010;31(12):1529-1537.
84. Ceconi C, Freedman SB, Tardif JC, et al; BEAUTIFUL Echo-BNP Investigators. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;14:408-414.
85. Troughton RW, Richards AM, Yandle TG, Frampton CM, Nicholls MG. The effects of medications on circulating levels of cardiac natriuretic peptides. Ann Med. 2007;39(4):242-260.
86. Difrancesco D. Funny channel gene mutations associated with arrhythmias. J Physiol. 2013;591(17):4117-4124.
87. Benezet-Mazuecos J, Rubio JM, Farré J, Quiñones MÁ, Sanchez-Borque P, Macía E. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol. 2013;36(7):830-836.
88. Kuwabara Y, Kuwahara K, Takano M, et al. Increased expression of HCN channels in the ventricular myocardium contributes to enhanced arrhythmicity in mouse failing hearts. J Am Heart Assoc. 2013;2(3): e000150.
89. Suenari K, Cheng CC, Chen YC, et al. Effects of ivabradine on the pulmonary vein electrical activity and modulation of pacemaker currents and calcium homeostasis. J Cardiovasc Electrophysiol. 2012;23(2): 200-206.
90. Plotnikov AN, Bucchi A, Shlapakova I, et al. HCN212-channel biological pacemakers manifesting ventricular tachyarrhythmias are responsive to treatment with I(f) blockade. Heart Rhythm. 2008;5(2):282-288.
91. Tamura A, Ogura T, Uemura H, et al. Effects of antiarrhythmic drugs on the hyperpolarization-activated cyclic nucleotide-gated channel current. J Pharmacol Sci. 2009;110(2):150-159.
92. Fan X, Chen Y, Wu P, et al. Novel electropharmacological activity of amiodarone on human HCN channels heterologously expressed in the Xenopus oocytes. Eur J Pharmacol. 2011;669(1-3):15-23.